{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T13:49:02Z","timestamp":1784641742643,"version":"3.55.0"},"reference-count":140,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have transformed modern cancer therapy by restoring antitumor T-cell responses through blockade of immune tolerance pathways such as CTLA-4 and PD-1\/PD-L1. However, the same immune activation that underlies their clinical efficacy can also lead to immune-related adverse events (irAEs), a broad spectrum of inflammatory and autoimmune toxicities that may affect virtually any organ system. The incidence and severity of these events vary according to the specific agent, tumor type, and treatment strategy. While irAEs have traditionally been attributed to dysregulated adaptive immunity, emerging evidence highlights a central and previously underappreciated role for innate immune mechanisms. In this review, we integrate the concepts of immunosurveillance and tumor immunoediting to illustrate how innate immunity contributes to both effective antitumor responses and immune-mediated toxicity. We describe how damage-associated signals and tumor microenvironment cues reprogram innate immune populations\u2014including neutrophils, macrophages, dendritic cells, myeloid-derived suppressor cells, and innate lymphoid cells\u2014toward pro-inflammatory or immunosuppressive states that influence therapeutic outcomes and toxicity risk. Finally, emerging biomarkers are highlighted and key knowledge gaps that currently limit the prediction and prevention of irAEs, positioning innate immunity as a critical regulatory axis and a promising target for developing strategies to mitigate toxicity without compromising anticancer efficacy.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1774615","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:46:33Z","timestamp":1776231993000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Role of innate immunity in the development of cancer immunotherapy immune-mediated adverse events"],"prefix":"10.3389","volume":"17","author":[{"given":"\u00c1lvaro","family":"Sierra-Salazar","sequence":"first","affiliation":[{"name":"Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n","place":["Mexico City, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yatzil","family":"Reyna-Ju\u00e1rez","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n","place":["Mexico City, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Alcal\u00e1-Carmona","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n","place":["Mexico City, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Quintana-Tenorio","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n","place":["Mexico City, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer T.","family":"Balderas-Miranda","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n","place":["Mexico City, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Camacho-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n","place":["Mexico City, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiram","family":"Torres-Ruiz","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n","place":["Mexico City, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.7326\/aitc202402200","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05705-5","article-title":"Cancer immunotherapy-related adverse events: causes and challenges","volume":"28","author":"Blidner","year":"2020","journal-title":"Support Care Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/antib13030059","article-title":"Adverse events of PD-1, PD-L1, CTLA-4, and LAG-3 immune checkpoint inhibitors: an analysis of the FDA adverse events database","volume":"13","author":"Frey","year":"2024","journal-title":"Antib (Basel)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41419-023-06391-x","article-title":"Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy","volume":"15","author":"Babamohamadi","year":"2024","journal-title":"Cell Death Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.07.004","article-title":"Clinical challenges of immune checkpoint inhibitors","volume":"38","author":"de Miguel","year":"2020","journal-title":"Cancer Cell"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1292122","article-title":"Achilles' heel of currently approved immune checkpoint inhibitors: immune related adverse events","volume":"15","author":"Yan","year":"2024","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.394","article-title":"Immune-related adverse events from immune checkpoint inhibitors","volume":"100","author":"Marrone","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2004.07.017","article-title":"The immunobiology of cancer immunosurveillance and immunoediting","volume":"21","author":"Dunn","year":"2004","journal-title":"Immunity"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-020-00950-x","article-title":"HMGB1 in inflammation and cancer","volume":"13","author":"Wang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-0684-y","article-title":"The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment","volume":"38","author":"De Marchi","year":"2019","journal-title":"Oncogene"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01444","article-title":"NLRP3 inflammasome activation in cancer: a double-edged sword","volume":"11","author":"Hamarsheh","year":"2020","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13046-025-03366-y","article-title":"Role of inflammasomes in cancer immunity: mechanisms and therapeutic potential","volume":"44","author":"Singh","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12964-023-01235-9","article-title":"Divergent functions of NLRP3 inflammasomes in cancer: a review","volume":"21","author":"Shadab","year":"2023","journal-title":"Cell Commun Signal"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.08.013","article-title":"The Nlrp3 inflammasome suppresses colorectal cancer metastatic growth in the liver by promoting natural killer cell tumoricidal activity","volume":"43","author":"Dupaul-Chicoine","year":"2015","journal-title":"Immunity"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/srep36107","article-title":"Targeting inflammasome\/IL-1 pathways for cancer immunotherapy","volume":"6","author":"Guo","year":"2016","journal-title":"Sci Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(00)04046-0","article-title":"Inflammation and cancer: back to Virchow","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.immuni.2017.08.018","article-title":"Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression","volume":"47","author":"Zhu","year":"2017","journal-title":"Immunity"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2024.152811","article-title":"Single-cell transcriptome analysis of macrophage subpopulations contributing to chemotherapy resistance in ovarian cancer","volume":"229","author":"Zhong","year":"2024","journal-title":"Immunobiology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13058-024-01887-6","article-title":"Single-cell transcriptional atlas of tumor-associated macrophages in breast cancer","volume":"26","author":"Zhang","year":"2024","journal-title":"Breast Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20180534","article-title":"Macrophages of distinct origins contribute to tumor development in the lung","volume":"215","author":"Loyher","year":"2018","journal-title":"J Exp Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1169560","article-title":"Damage-mediated macrophage polarization in sterile inflammation","volume":"14","author":"Koncz","year":"2023","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001341","article-title":"Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer","volume":"9","author":"Li","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13235885","article-title":"The role of innate immune cells in tumor invasion and metastasis","volume":"13","author":"Huang","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26025","article-title":"TIE2-expressing monocytes: a novel cellular biomarker for hepatocellular carcinoma","volume":"57","author":"De Palma","year":"2013","journal-title":"Hepatology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.02.005","article-title":"Intertwined regulation of angiogenesis and immunity by myeloid cells","volume":"36","author":"Rivera","year":"2015","journal-title":"Trends Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01380","article-title":"Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid Malignancies","volume":"9","author":"Chao","year":"2019","journal-title":"Front Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1370765","article-title":"NETosis: a new factor in tumor progression and cancer-associated thrombosis","volume":"40","author":"Demers","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1172\/jci67484","article-title":"Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis","volume":"123","author":"Cools-Lartigue","year":"2013","journal-title":"J Clin Invest"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2394-6","article-title":"DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25","volume":"583","author":"Yang","year":"2020","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-sitc2020.0755","article-title":"CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity","volume":"52","author":"Teijeira","year":"2020","journal-title":"Immunity"},{"key":"B36","doi-asserted-by":"publisher","first-page":"361ra138","DOI":"10.1126\/scitranslmed.aag1711","article-title":"Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps","volume":"8","author":"Park","year":"2016","journal-title":"Sci Transl Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01749","article-title":"The emerging role of neutrophil extracellular traps (NETs) in tumor progression and metastasis","volume":"11","author":"Masucci","year":"2020","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01127-z","article-title":"Innate lymphoid cells and cancer","volume":"23","author":"Jacquelot","year":"2022","journal-title":"Nat Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","article-title":"Roles of natural killer cells in immunity to cancer, and applications to immunotherapy","volume":"23","author":"Wolf","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1420205","article-title":"The basic biology of NK cells and its application in tumor immunotherapy","volume":"15","author":"Jiang","year":"2024","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0730640100","article-title":"Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells","volume":"100","author":"Castriconi","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02689","article-title":"Impairment of NKG2D-mediated tumor immunity by TGF-beta","volume":"10","author":"Lazarova","year":"2019","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-09-2123","article-title":"Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity","volume":"69","author":"Kopp","year":"2009","journal-title":"Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.04.004","article-title":"MDSC: markers, development, states, and unaddressed complexity","volume":"54","author":"Hegde","year":"2021","journal-title":"Immunity"},{"key":"B45","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12943-022-01657-y","article-title":"Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy","volume":"21","author":"Wu","year":"2022","journal-title":"Mol Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00846-y","article-title":"Myeloid-derived suppressor cells in cancer and cancer therapy","volume":"21","author":"Lasser","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2175-3","article-title":"Targeting myeloid-derived suppressor cells for cancer immunotherapy","volume":"67","author":"Liu","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00109","article-title":"The generation and identity of human myeloid-derived suppressor cells","volume":"10","author":"Bergenfelz","year":"2020","journal-title":"Front Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-21-0764","article-title":"Myeloid-derived suppressor cells: a propitious road to clinic","volume":"11","author":"Grover","year":"2021","journal-title":"Cancer Discov"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines4040036","article-title":"The role of myeloid-derived suppressor cells (MDSC) in cancer progression","volume":"4","author":"Umansky","year":"2016","journal-title":"Vaccines (Basel)"},{"key":"B52","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature07750","article-title":"Identification of a dendritic cell receptor that couples sensing of necrosis to immunity","volume":"458","author":"Sancho","year":"2009","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00859-1","article-title":"Dendritic cells as orchestrators of anticancer immunity and immunotherapy","volume":"21","author":"Heras-Murillo","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.06.003","article-title":"Critical role for CD103(+)\/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma","volume":"30","author":"Roberts","year":"2016","journal-title":"Cancer Cell"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20092618","article-title":"Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells","volume":"207","author":"Poulin","year":"2010","journal-title":"J Exp Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-373944","article-title":"The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells","volume":"119","author":"Schreibelt","year":"2012","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.1038\/s41467-020-19192-z","article-title":"Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s","volume":"11","author":"Oba","year":"2020","journal-title":"Nat Commun"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.06.014","article-title":"Lymphatic-localized Treg-mregDC crosstalk limits antigen trafficking and restrains anti-tumor immunity","volume":"42","author":"You","year":"2024","journal-title":"Cancer Cell"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2134-y","article-title":"A conserved dendritic-cell regulatory program limits antitumour immunity","volume":"580","author":"Maier","year":"2020","journal-title":"Nature"},{"key":"B60","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41392-024-02049-y","article-title":"Neutrophil diversity and function in health and disease","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.08.048","article-title":"The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry","volume":"158","author":"Ruste","year":"2021","journal-title":"Eur J Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1234142","article-title":"Neutrophil to lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/cai2.163","article-title":"Predictive value of neutrophil-to-lymphocyte ratio for immune checkpoint inhibitor-related myocarditis among patients treated for non-small-cell lung cancer","volume":"4","author":"Xue","year":"2025","journal-title":"Cancer Innov"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061308","article-title":"Neutrophil-to-lymphocyte ratio predicts development of immune-related adverse events and outcomes from immune checkpoint blockade: a case-control study","volume":"13","author":"Lee","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/nri3024","article-title":"Neutrophils in the activation and regulation of innate and adaptive immunity","volume":"11","author":"Mantovani","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002242","article-title":"Neutrophils in the era of immune checkpoint blockade","volume":"9","author":"Faget","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100419","article-title":"Multiplexed imaging reveals an IFN-gamma-driven inflammatory state in nivolumab-associated gastritis","volume":"2","author":"Ferrian","year":"2021","journal-title":"Cell Rep Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1346687","article-title":"Identification of immunological patterns characterizing immune-related psoriasis reactions in oncological patients in therapy with anti-PD-1 checkpoint inhibitors","volume":"15","author":"Morelli","year":"2024","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316948","article-title":"Enterocolitis due to immune checkpoint inhibitors: a systematic review","volume":"67","author":"Soularue","year":"2018","journal-title":"Gut"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2022.09.002","article-title":"Neutrophil-epithelial crosstalk during intestinal inflammation","volume":"14","author":"Kang","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11051496","article-title":"Checkpoint inhibitor-induced colitis: an update","volume":"11","author":"Losurdo","year":"2023","journal-title":"Biomedicines"},{"key":"B72","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s00520-024-08889-2","article-title":"Immune checkpoint inhibitor-induced diarrhea and colitis: an overview","volume":"32","author":"Zoghbi","year":"2024","journal-title":"Support Care Cancer"},{"key":"B73","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.it.2024.11.014","article-title":"Targeting molecular pathways to control immune checkpoint inhibitor toxicities","volume":"46","author":"Reschke","year":"2025","journal-title":"Trends Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00292","article-title":"FcgammaR-binding is an important functional attribute for immune checkpoint antibodies in cancer immunotherapy","volume":"10","author":"Chen","year":"2019","journal-title":"Front Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242417583","article-title":"How neutrophils shape the immune response: reassessing their multifaceted role in health and disease","volume":"24","author":"Shafqat","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005657","article-title":"Tumor-associated neutrophils and macrophages exacerbate antidrug IgG-mediated anaphylactic reaction against an immune checkpoint inhibitor","volume":"10","author":"Arai","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v7.i12.829","article-title":"Do neutrophil extracellular traps contribute to the heightened risk of thrombosis in inflammatory diseases","volume":"7","author":"Rao","year":"2015","journal-title":"World J Cardiol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00787-0","article-title":"Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseases","volume":"23","author":"Wigerblad","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"9029","DOI":"10.1038\/s41598-021-88307-3","article-title":"Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors","volume":"11","author":"Michailidou","year":"2021","journal-title":"Sci Rep"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14020302","article-title":"Biomarkers associated with immune-related adverse events under checkpoint inhibitors in metastatic melanoma","volume":"14","author":"W\u00f6lffer","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B81","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s00011-024-01979-1","article-title":"Mediation of macrophage M1 polarization dynamics change by ubiquitin-autophagy-pathway regulated NLRP3 inflammasomes in PD-1 inhibitor-related myocardial inflammatory injury","volume":"74","author":"Chen","year":"2025","journal-title":"Inflammation Res"},{"key":"B82","doi-asserted-by":"publisher","first-page":"89","DOI":"10.21203\/rs.3.rs-841797\/v1","article-title":"Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients","volume":"22","author":"Baek","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0075","article-title":"Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1111\/cup.13454","article-title":"Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14(+) and CD16(+) monocytes driving an innate immune response","volume":"46","author":"Curry","year":"2019","journal-title":"J Cutan Pathol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13075-022-02737-6","article-title":"Tumor necrosis factor alpha neutralization attenuates immune checkpoint inhibitor-induced activation of intermediate monocytes in synovial fluid mononuclear cells from patients with inflammatory arthritis","volume":"24","author":"S\u00f8rensen","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.02.008","article-title":"Activation and transcriptional profile of monocytes and CD8(+) T cells are altered in checkpoint inhibitor-related hepatitis","volume":"75","author":"Gudd","year":"2021","journal-title":"J Hepatol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12061140","article-title":"Activation of CD14+ monocytes via the IFN-gamma signaling pathway is associated with immune-related adverse events in hepatocellular carcinoma patients receiving PD-1 inhibition combination therapy","volume":"12","author":"Song","year":"2024","journal-title":"Biomedicines"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02254","article-title":"Immunopathogenesis of immune checkpoint inhibitor-related adverse events: roles of the intestinal microbiome and Th17 cells","volume":"10","author":"Anderson","year":"2019","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.837645","article-title":"The role of immune checkpoint molecules on macrophages in cancer, infection, and autoimmune pathologies","volume":"13","author":"Brom","year":"2022","journal-title":"Front Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1199631","article-title":"Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy","volume":"14","author":"Xu","year":"2023","journal-title":"Front Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-023-10257-z","article-title":"Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade","volume":"41","author":"Wang","year":"2024","journal-title":"Clin Exp Metastasis"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1232269","article-title":"Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1beta and interleukin-6: biochemical implications in cardio-immuno-oncology","volume":"11","author":"Quagliariello","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.2147\/jir.s348464","article-title":"Protective effect of crocin on immune checkpoint inhibitors-related myocarditis through inhibiting NLRP3 mediated pyroptosis in cardiomyocytes via NF-kappaB pathway","volume":"15","author":"Zhang","year":"2022","journal-title":"J Inflammation Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010127","article-title":"Targeting the NLRP3 inflammasome abrogates cardiotoxicity of immune checkpoint blockers","volume":"13","author":"Lu","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000958","article-title":"Immune checkpoint inhibitor-associated celiac disease","volume":"8","author":"Badran","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1207544","article-title":"Cutaneous immune-related adverse events to immune checkpoint inhibitors: from underlying immunological mechanisms to multi-omics prediction","volume":"14","author":"Cao","year":"2023","journal-title":"Front Immunol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000210031","article-title":"Immune checkpoint inhibitor myopathy: the double-edged sword of cancer immunotherapy","volume":"103","author":"Beecher","year":"2024","journal-title":"Neurology"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.06.001","article-title":"Molecular pathways of colon inflammation induced by cancer immunotherapy","volume":"182","author":"Luoma","year":"2020","journal-title":"Cell"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izad229","article-title":"Focus on immune checkpoint inhibitors-related intestinal inflammation: From pathogenesis to therapeutical approach","volume":"30","author":"Del Gaudio","year":"2024","journal-title":"Inflammation Bowel Dis"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02764","article-title":"Dynamics of colon monocyte and macrophage activation during colitis","volume":"9","author":"Jones","year":"2018","journal-title":"Front Immunol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/1078-0432.ccr-19-1868","article-title":"Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade","volume":"26","author":"House","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04696-0","article-title":"Characterization of immunomodulatory factors and cells in bronchoalveolar lavage fluid for immune checkpoint inhibitor-related pneumonitis","volume":"149","author":"Wang","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000001298","article-title":"Clinical and histopathologic features of immune checkpoint inhibitor-related pneumonitis","volume":"43","author":"Larsen","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/circulationaha.122.062551","article-title":"Expansion of pathogenic cardiac macrophages in immune checkpoint inhibitor myocarditis","volume":"149","author":"Ma","year":"2024","journal-title":"Circulation"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00715-5","article-title":"Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart","volume":"24","author":"Munir","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B108","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/imr.13240","article-title":"Mediators and mechanisms of immune checkpoint inhibitor-associated myocarditis: Insights from mouse and human","volume":"318","author":"Gong","year":"2023","journal-title":"Immunol Rev"},{"key":"B109","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1161\/circresaha.124.324260","article-title":"Visualizing immune checkpoint inhibitors derived inflammation in atherosclerosis","volume":"135","author":"Lou","year":"2024","journal-title":"Circ Res"},{"key":"B110","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s11033-025-11095-w","article-title":"Cytokine profiling of patients with immune checkpoint inhibitor-associated myocarditis: a pilot study","volume":"52","author":"Li","year":"2025","journal-title":"Mol Biol Rep"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.2147\/jir.s531641","article-title":"Integrated single-cell analysis reveals the heterogeneity of tumor-associated macrophages and their implications for immunotherapy in colorectal cancer","volume":"18","author":"Xu","year":"2025","journal-title":"J Inflammation Res"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113401","article-title":"Targeting tumor-associated macrophages to increase the efficacy of immune checkpoint inhibitors: A glimpse into novel therapeutic approaches for metastatic melanoma","volume":"12","author":"Ceci","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2021.101481","article-title":"The role of dendritic cells in cancer and anti-tumor immunity","volume":"52","author":"Marciscano","year":"2021","journal-title":"Semin Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.10.020","article-title":"Type I interferon activates MHC class I-dressed CD11b(+) conventional dendritic cells to promote protective anti-tumor CD8(+) T cell immunity","volume":"55","author":"Duong","year":"2022","journal-title":"Immunity"},{"key":"B115","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.1038\/s41467-020-18570-x","article-title":"PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade","volume":"11","author":"Peng","year":"2020","journal-title":"Nat Commun"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/nri1457","article-title":"IDO expression by dendritic cells: tolerance and tryptophan catabolism","volume":"4","author":"Mellor","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00262-024-03754-x","article-title":"High expression of PD-L1 on conventional dendritic cells in tumour-draining lymph nodes is associated with poor prognosis in oral cancer","volume":"73","author":"Hjalmarsson","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav7431","article-title":"Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy","volume":"12","author":"Mayoux","year":"2020","journal-title":"Sci Transl Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.03.039","article-title":"Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma","volume":"77","author":"Chuah","year":"2022","journal-title":"J Hepatol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.35772\/ghm.2022.01052","article-title":"Association between increased peripheral blood CD86-positive plasmacytoid dendritic cells and immune-related adverse events in patients with non-small cell lung cancer","volume":"4","author":"Karayama","year":"2022","journal-title":"Glob Health Med"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1266850","article-title":"Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management","volume":"15","author":"Lin","year":"2024","journal-title":"Front Immunol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08105-5","article-title":"Immune responses in checkpoint myocarditis across heart, blood and tumour","volume":"636","author":"Blum","year":"2024","journal-title":"Nature"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.01.024","article-title":"Immune profiling of dermatologic adverse events from checkpoint blockade using tissue cyclic immunofluorescence: A pilot study","volume":"144","author":"Maliga","year":"2024","journal-title":"J Invest Dermatol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-23-3431","article-title":"Immunologic profiling of immune-related cutaneous adverse events with checkpoint inhibitors reveals polarized actionable pathways","volume":"30","author":"Lacouture","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-24-0387","article-title":"Deep immune phenotyping reveals distinct immunopathogenesis in checkpoint inhibitor-induced colitis compared with ulcerative colitis","volume":"13","author":"Pesch","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B126","doi-asserted-by":"publisher","first-page":"494","DOI":"10.2139\/ssrn.3554064","article-title":"Mutant p53 suppresses innate immune signaling to promote tumorigenesis","volume":"39","author":"Ghosh","year":"2021","journal-title":"Cancer Cell"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-019-0224-x","article-title":"Sustained type I interferon signaling as a mechanism of resistance to PD-1 blockade","volume":"29","author":"Jacquelot","year":"2019","journal-title":"Cell Res"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16091759","article-title":"Kinetics of IFNgamma-induced cytokines and development of immune-related adverse events in patients receiving PD-(L)1 inhibitors","volume":"16","author":"Alserawan","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012414","article-title":"Innate and adaptive immune features associated with immune-related adverse events","volume":"13","author":"Khan","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008078","article-title":"Therapeutic inhibition of monocyte recruitment prevents checkpoint inhibitor-induced hepatitis","volume":"12","author":"Gudd","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0155-1","article-title":"Immune dysregulation in cancer patients developing immune-related adverse events","volume":"120","author":"Khan","year":"2019","journal-title":"Br J Cancer"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.immuni.2018.09.024","article-title":"Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-gamma and IL-12","volume":"55","author":"Garris","year":"2022","journal-title":"Immunity"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-023-02805-4","article-title":"Deciphering pathogenic cellular module at single-cell resolution in checkpoint inhibitor-related pneumonitis","volume":"42","author":"Cui","year":"2023","journal-title":"Oncogene"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1112409","article-title":"Eosinophil and IFN-gamma associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy","volume":"14","author":"Hu","year":"2023","journal-title":"Front Immunol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2022.12.007","article-title":"Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors","volume":"4","author":"Nu\u00f1ez","year":"2023","journal-title":"Med"},{"key":"B136","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2024.11.011","article-title":"Cytokines in cancer","volume":"43","author":"Kureshi","year":"2025","journal-title":"Cancer Cell"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1403771","article-title":"Myeloid-derived suppressor cells in peripheral blood as predictive biomarkers in patients with solid tumors undergoing immune checkpoint therapy: systematic review and meta-analysis","volume":"15","author":"M\u00f6ller","year":"2024","journal-title":"Front Immunol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2023.2247303","article-title":"Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs","volume":"12","author":"Lepper","year":"2023","journal-title":"Oncoimmunology"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061446","article-title":"Specific patterns of blood ILCs in metastatic melanoma patients and their modulations in response to immunotherapy","volume":"13","author":"Rethacker","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-242075","article-title":"Presumed complement-mediated, checkpoint inhibitor-induced, thrombotic microangiopathy in a patient with metastatic melanoma","volume":"14","author":"Muniz","year":"2021","journal-title":"BMJ Case Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1774615\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:46:34Z","timestamp":1776231994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1774615\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":140,"alternative-id":["10.3389\/fimmu.2026.1774615"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1774615","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"article-number":"1774615"}}